IQV — IQVIA Holdings Inc.

IQVIA Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $4.368 billion, up 8.7% year-over-year (8.5% at constant currency).
• Adjusted EBITDA: $994 million, representing a 9.2% increase year-over-year.
• Adjusted Diluted EPS: $3.15, exceeding guidance and up 12.1% year-over-year.
• Organic Growth: Accelerated to 6% year-over-year, three times the rate from the previous year.
• R&D Solutions Revenue: $2.575 billion, up 8.8% reported.
• Commercial Solutions Revenue: $1.793 billion, up 8.6% reported.
• Net New Bookings: $3.15 billion, a 19% increase year-over-year, with a book-to-bill ratio of 1.22.
• Cash Flow: Free cash flow of $360 million, up 23% year-over-year.
• Net Debt: $14.09 billion, with a net leverage ratio of 3.59x trailing 12-month adjusted EBITDA.

2. Strategic Updates and Business Highlights

• Market Conditions: Improved demand environment with strong RFP flow growth and funding for emerging biopharma (EBP) increasing significantly.
• Customer Segmentation: New classification of customer segments to benchmark against CRO peers; large pharma (50% of R&D revenue), midsize (15%), and EBP (35%).
• AI Integration: Continued focus on AI capabilities in clinical trials and commercial solutions, enhancing operational efficiency and client engagement.
• Acquisitions: Completed acquisition of Charles River assets, contributing to revenue growth.
• Regulatory Engagement: Active participation in discussions with U.S. health authorities on clinical trial innovation.

3. Forward Guidance and Outlook

• Full-Year 2026 Guidance: Revenue expected between $17.275 billion and $17.475 billion (5.9% to 7.1% growth). Adjusted EBITDA guidance raised to $4 billion - $4.05 billion (5.6% to 6.9% growth). Adjusted diluted EPS guidance raised to $12.80 - $13.00 (7.4% to 9.1% growth).
• Q3 2026 Guidance: Revenue expected between $4.15 billion and $4.39 billion (5.2% to 7.1% growth), adjusted EBITDA between $1 billion and $1.02 billion (5.4% to 7.5% growth), and adjusted diluted EPS between $3.19 and $3.29 (6.3% to 9.7% growth).

4. Bad News, Challenges, or Points of Concern

• Foreign Exchange Impact: FX is expected to have less of a tailwind than previously anticipated, which could affect margins.
• Pass-Through Revenue: Continued growth in pass-throughs is a headwind for margins as they come with no profit.
• Competitive Landscape: While the company is gaining market share, increased competition from other CROs remains a concern, especially regarding pricing and capabilities.

5. Notable Q&A Insights

• Bookings Profile: Management confirmed that the strong bookings were broad-based with no unusual or concerning trends noted; cancellations remained within historical norms.
• Outsourcing Trends: Increased demand for CRO services is anticipated due to the extensive use of AI in drug discovery, with clients expecting to double their study portfolios.
• AI Investments: The company is focusing on proprietary healthcare data and deep domain knowledge to enhance AI capabilities, with significant investments in this area.
• Competitive Dynamics: Discussions in competitive RFPs focus more on delivery capabilities and technology rather than pricing, reflecting a shift in client priorities.

Overall, IQVIA reported strong financial performance in Q2 2026, driven by robust demand in both clinical and commercial segments, while also raising its guidance for the year. However, challenges such as foreign exchange impacts and competitive pressures remain pertinent.